UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
  
 
FORM 6-K
 
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
For the month of February 2020
 
 
Commission File Number:  001-39034
 
 
BELLUS HEALTH INC.

(Name of registrant)

275 Armand-Frappier Blvd.
 Laval, Québec
 H7V 4A7
Canada

(Address of principal executive offices)


Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
 
☐   Form 20-F
☒   Form 40-F
 
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐


 SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
BELLUS Health Inc.
 
       
Date: February 20, 2020
By:
 /s/ François Desjardins
 
   
Name:   François Desjardins
   
Title:     Vice President, Finance


Form 6-K Exhibit Index
 
Exhibit
Number
 
Document Description
 
 
 
 

Exhibit 99.1
 
BELLUS Health Inc.
275 Armand Frappier Blvd.
Laval, Quebec, Canada H7V 4A7



BELLUS Health to Present at Two Upcoming Healthcare Investor Conferences
 
LAVAL, Quebec, February 20, 2020 – BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, President and Chief Executive Officer of BELLUS Health, will participate in two upcoming healthcare investor conferences.
 
Conference Presentation Details:
 
Event: SVB Leerink 9th Annual Global Healthcare Conference
 
Date/Time: Thursday, February 27, 2020 at 10:00 a.m. EST
 
Location: New York, NY
 

Event: Cowen and Company's 40th Annual Health Care Conference
 
Date/Time: Tuesday, March 3, 2020 at 8:00 a.m. EST
 
Location: Boston, MA

Live webcasts from the Leerink fireside chat and the Cowen conference presentation may be accessed on the Events and Presentations page under the Investors & News section of BELLUS Health's website at www.bellushealth.com. Following the events, archived webcasts and presentations will be available on the Company’s website.
 
About BELLUS Health (www.bellushealth.com)
 
BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders. The Company's product candidate, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus.
 
Chronic cough, the lead indication for BLU-5937, is a cough lasting more than eight weeks and is associated with significant adverse physical, social and psychosocial effects on health and quality of life. It is estimated that approximately 26 million adults in the United States suffer from chronic cough with more than 2.6 million having refractory chronic cough lasting for more than a year. There is no specific therapy approved for refractory chronic cough and treatment options are limited.
 
Chronic pruritus, commonly known as chronic itch, is an irritating sensation that leads to scratching, and persists for longer than six weeks, which can be debilitating and has a significant impact on quality-of-life. It is a hallmark of many conditions, including atopic dermatitis (“AD”). It is estimated that chronic pruritus associated with AD affects more than 16.9 million adults in the United States.

BELLUS Health Inc.
275 Armand Frappier Blvd.
Laval, Quebec, Canada H7V 4A7



FOR MORE INFORMATION, PLEASE CONTACT:
 
Investors:
BELLUS Health
François Desjardins
Vice-President, Finance
450-680-4525
fdesjardins@bellushealth.com
 
Solebury Trout
Chad Rubin
646-378-2947
crubin@troutgroup.com
 
Media:
Solebury Trout
Joshua R. Mansbach
646-378-2964
jmansbach@troutgroup.com
 
SOURCE: BELLUS Health Inc.